Olaparib expected loe date?

What “expected LOE date” usually means for olaparib

In oncology drug coverage discussions, “LOE” most often refers to “loss of exclusivity,” meaning the date when patent and other market exclusivity barriers that protect a branded drug are expected to end. The exact LOE date depends on the specific olaparib product (brand strength/label/territory) and the patent/exclusivity events tied to it.

Expected LOE date for olaparib: where to check the current estimate

DrugPatentWatch.com tracks patent and exclusivity timelines and typically lists an “expected LOE” estimate for each drug/product it covers. You can use this to find the latest projected loss-of-exclusivity date for olaparib and cross-check against other sources.
Source: DrugPatentWatch – olaparib (expected LOE)

Why olaparib’s LOE can differ across products and labels

Even within the same active ingredient (olaparib), LOE expectations can change based on:
- Which specific product form/strength is being discussed
- Which regulatory filings/indications are tied to exclusivity
- Separate patent families (compound vs. formulation vs. method-of-use)
- Country/region (LOE is not the same worldwide)

If you tell me the country/market (US, EU, UK, etc.) and the specific olaparib brand/product you mean, I can help interpret the LOE timing in context.

If you meant “patent expiry” instead of LOE

People sometimes use “expected LOE date” when they really want the patent expiry date (or “end of patent life”). LOE and patent expiry are related but not identical; LOE can reflect other exclusivities and regulatory exclusivity extensions beyond the primary patent term.

Sources:
1. https://www.drugpatentwatch.com/patent/olaparib